Stroke, Vol 22, 1064-1067, Copyright © 1991 by American Heart Association
M Marinov and H Wassmann
We evaluated the influence of a continuous intravenous infusion of 0.24
mg/kg PN 200-110 started 20 minutes before the induction of ischemia and
continued for 2 hours on infarct size, histopathology, and neurological
outcome in middle cerebral artery-occluded rats treated with PN 200-110 (n
= 8), placebo (n = 7), or saline (n = 8). Neurological examination was
performed 24 hours after occlusion. We quantified infarct size by
2,3,5-triphenyl-tetrazolium chloride, hematoxylin and eosin, and Nissl
staining and by computerized analysis of tracings of the infarcted areas
and evaluated neuronal injury at the infarct periphery. The different types
of ischemic cell damage were quantified by direct visual counting. We found
no differences among saline-, placebo-, and PN 200-110-treated rats
regarding infarct size, amount of neuronal alteration, and neurological
outcome. Our results indicate the lack of a significant protective effect
of this drug in experimental focal ischemia.
ARTICLES
Lack of effect of PN 200-110 on neuronal injury and neurological outcome in middle cerebral artery-occluded rats
Department of Neurosurgery, Medical Academy, Sofia, Bulgaria.
This article has been cited by other articles:
![]() |
S. J. Bailey, N. I. Wood, N. A. Samson, A. L. Rothaul, J. C. Roberts, P. D. King, T. C. Hamilton, D. C. Harrison, and A. J. Hunter Failure of Isradipine to Reduce Infarct Size in Mouse, Gerbil, and Rat Models of Cerebral Ischemia Stroke, November 1, 1995; 26(11): 2177 - 2183. [Abstract] [Full Text] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1991 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |